BTEE:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (USD)

ETF | Others |

Last Closing

USD 6.093

Change

+0.01 (+0.21)%

Market Cap

USD 0.49B

Volume

2.21K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

+180.00 (+2.15%)

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

+280.00 (+3.37%)

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

-1.50 (-0.80%)

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.04 (-0.27%)

USD 642.91B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.04 (-0.24%)

USD 636.40B
0R1I:LSE NVIDIA Corp.

+5.05 (+0.54%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+5.75 (+0.28%)

USD 320.04B
0QZK:LSE Coca-Cola Co.

+0.40 (+0.63%)

USD 266.08B
0QZO:LSE 0QZO

+1.30 (+1.27%)

USD 258.54B

ETFs Containing BTEE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.54% 16% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.54% 15% F 27% F
Trailing 12 Months  
Capital Gain 0.02% 27% F 41% F
Dividend Return 0.23% 39% F 67% D+
Total Return 0.25% 25% F 41% F
Trailing 5 Years  
Capital Gain 24.94% 50% F 61% D-
Dividend Return 0.66% 25% F 16% F
Total Return 25.59% 48% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 6.60% 61% D- 65% D
Dividend Return 6.71% 60% D- 64% D
Total Return N/A 100% F 98% N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.77% 36% F 50% F
Risk Adjusted Return 33.92% 56% F 68% D+
Market Capitalization 0.49B 70% C- 60% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.